NICE deems daclizumab cost effective to treat MS patients
NICE deems daclizumab cost effective to treat MS patients
The National Institute of Health and Care Excellence (NICE) has announced daclizumab as a cost effective treatment for people with relapsing remitting MS (RRMS)...Read more - http://www.ms-uk.org/nice-deems-daclizu ... nts-170317
MS-UK - http://www.ms-uk.org/